As the severity of gliomas increases from Grade II/III to Grade IV, there is a corresponding rise in TIM-3 expression on CD4+ and CD8+ T cells and increased GAL-9 expression within tumors. This evidence concerns the gene HAVCR2 and central nervous system cancer.